January 20, 2017 2:16 PM ET


Company Overview of F. Hoffmann-La Roche Ltd

Company Overview

F. Hoffmann-La Roche Ltd. provides in-vitro diagnostics and drugs for cancer and transplantation. The company specializes in medicines for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. Its products include cancer treatments, such as Avastin, Herceptin, and MabThera that are also effective in the treatment of rheumatoid arthritis, anemia, and osteoporosis. The company also researches, develops, and produces molecular diagnostic reagents, test systems, and test kits. In addition, it provides automated instruments, software, consumables, and IT solutions used in in-vitro diagnostic...


Grenzacherstrasse 124

Basel,  4070


Founded in 1896


41 61 688 11 11


41 61 691 93 91

Key Executives for F. Hoffmann-La Roche Ltd

Chief Executive Officer of Roche Group
Age: 49
Head of Roche Basel Site
Compensation as of Fiscal Year 2016.

F. Hoffmann-La Roche Ltd Key Developments

F. Hoffmann-La Roche Ltd to Report Q3, 2016 Sales/Trading Statement Results on Oct 20, 2016

F. Hoffmann-La Roche Ltd announced that they will report Q3, 2016 sales/trading statement results on Oct 20, 2016

F. Hoffmann-La Roche Ltd. Reports Earnings Results for the Six Months Ended June 30, 2016

F. Hoffmann-La Roche Ltd. reported earnings results for the six months ended June 30, 2016. For the six months, the company reported net income attributable to shareholders was CHF 5.38 billion, or CHF 6.24 per diluted share, compared to CHF 5.15 billion, or CHF 5.98 per diluted share, for the same period a year ago. Sales were CHF 25.02 billion, compared to CHF 23.58 billion for the same period a year ago. Operating profit was CHF 8.14 billion, compared to CHF 7.71 billion for the same period a year ago. Profit before taxes was CHF 7.52 billion, compared to CHF 7.08 billion for the same period a year ago.

F. Hoffmann-La Roche Ltd Presents at 16th Annual Biotech in Europe Forum, Sep-27-2016 through Sep-28-2016

F. Hoffmann-La Roche Ltd Presents at 16th Annual Biotech in Europe Forum, Sep-27-2016 through Sep-28-2016. Venue: MCH Messe Schweiz (Basel) AG, Messepl. 21, CH-4058 Basel, Switzerland. Presentation Date & Speakers: Sep-27-2016, Maria Bobadilla, William Pao, Global Head of the Oncology Discovery and Translational Area (DTA), Roche Pharmaceutical Research & Early Development (pRED).

Similar Private Companies By Industry

Company Name Region
Acino International AG Europe
Activen SA Europe
AL-S Pharma AG Europe
Albea Pharmaceuticals AG Europe
Alpen Pharma AG Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact F. Hoffmann-La Roche Ltd, please visit www.roche.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.